saged

A person with ovaries is typically born with about one million ovarian follicles.¹ By puberty, this number decreases to between 250,000 and 400,000¹, continuing to decline throughout life. Between the ages of 45-56, the diminishing ovarian follicle count leads to hormonal shifts that can cause various symptoms, including irregular menstruation and vasomotor or organ-related issues.¹ This transitional phase is known as perimenopause, while menopause marks the final menstrual cycle. This module explores the potential of medical cannabis to alleviate disruptive symptoms associated with menopause, offering an alternative option for symptom management. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the physiology, symptomatology and effects of menopause Identify conventional interventions for symptoms of menopause and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of menopause Identify considerations and risks for selecting medical cannabis products to treat symptoms of menopause References ¹ Peacock, Kimberly, and Kari M. Ketvertis. “Menopause.” NIH, StatPearls Publishing, Jan. 2024, www.ncbi.nlm.nih.gov/books/NBK507826/. Accessed 26 June 2024.

This module provides healthcare practitioners with a foundational understanding of mental health conditions, focussing on their prevalence, underlying mechanisms, and clinical impact—particularly in the Australian context. By examining the characteristics and pathophysiology of common conditions, practitioners will better understand current treatment limitations and the growing interest in alternative or adjunctive options such as medical cannabis.The module explores the potential mechanisms through which medical cannabis may alleviate specific symptoms associated with mental health conditions, while also addressing the limitations and risks of its use in this context. Evidence-based strategies for risk mitigation and safe prescribing are presented to support informed, patient-centred decision-making.Upon completion, practitioners will be better equipped to evaluate the appropriate role of medical cannabis in mental health care and to integrate it safely and effectively into treatment plans where clinically appropriate. Preview this module by watching the video above. Estimated Duration: 1 hours Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Define mental health and mental health conditions Explain the prevalence and impact of mental health issues in Australia Identify key risk factors for developing mental health conditions in Australia Describe the characteristics, pathophysiology, and treatment options for common mental health conditions Explain how medical cannabis may alleviate symptoms of mental health conditions through its primary mechanisms of action Describe the therapeutic potential of medical cannabis for treating symptoms of common mental health conditions Outline potential risks of medical cannabis treatment for mental health symptoms and discuss risk management strategies where appropriate

Patient Conversations: Why Cultural Safety Matters in Medical Cannabis Prescribing Published: July 2025 As medical cannabis becomes an increasingly accepted therapeutic option in Australia, healthcare professionals should consider not only the clinical aspects of prescribing, but also the cultural safety of their practice. For many patients, particularly Aboriginal and Torres Strait Islander peoples and those from culturally and linguistically diverse (CALD) communities, engaging with the healthcare system can carry risks of misunderstanding, harm, and marginalisation if cultural needs are not recognised and respected.1,2 What exactly is “Cultural Safety”? Cultural safety is a patient-led concept that focuses on whether individuals feel respected, heard, and safe during healthcare encounters.3 It goes beyond merely being aware of cultural differences (i.e. "cultural awareness”) and requires healthcare professionals to reflect on their own biases, power, and privilege while actively adapting their care to meet the needs of the patient’s cultural identity and lived experience.4 Ultimately, it is the patient, not the healthcare professional, who determines whether an experience is culturally safe.3 Why is this important for medical cannabis? Medical cannabis use can be influenced by personal, cultural, legal, and social factors. Patients may have concerns regarding stigma, legality, or family and community expectations.5 For some, complementary medicines may resonate with cultural healing traditions.6 For others, medical cannabis may invoke social stigma from within their communities.6 For Aboriginal and Torres Strait Islander peoples, the impacts of colonisation, systemic racism, and intergenerational trauma can contribute to distrust of mainstream healthcare.1 For CALD communities, differing views about health, medicine, and healing may shape how medical cannabis is perceived.6 Practical considerations for culturally safe medical cannabis prescribing Stigma Acknowledge the historical criminalisation of cannabis and its disproportionate impact on some communities6,7: Be prepared to address patient concerns about legal issues, confidentiality, and fear of judgement. Recognise that concerns around stigma may be heightened among Aboriginal and Torres Strait Islander peoples and CALD patients, who may have previously experienced discrimination within healthcare and legal systems.8,9 Creating a safe, non-judgemental space is essential. This involves using inclusive and respectful language, and reassuring patients about the confidentiality of their care, and the legal and clinical appropriateness of prescribed medical cannabis.8 For Aboriginal and Torres Strait Islander patients, it is important to understand the impact of intergenerational trauma and to approach care with cultural humility and respect for their lived experiences.9 Access and equity Understand that cost, geographic barriers, and language barriers can impact access to medical cannabis.10 Share options and advocate for equitable prescribing pathways, such as the Compassionate Access Schemes offered in some states11 and through selected medical cannabis organisations. Provide translated information where available, engage with interpreters, and guide patients through application processes.8 For Aboriginal and Torres Strait Islander patients, consider the added importance of family and community in decision-making and support models: Collaborate with Aboriginal Health Workers or Aboriginal Community Controlled Health Services (ACCHSs) to provide culturally appropriate care.9 Cultural perceptions Some patients may see cannabis as an extension of traditional medicine6, while others may associate it with substance misuse or illegality6: Approach these discussions with curiosity, not assumptions. Explore patients’ beliefs about healing and medicine, and be open to integrating their cultural practices with medical care where safe and appropriate.8 For Aboriginal and Torres Strait Islander patients, acknowledge the importance of connection to Country, spiritual wellbeing, and traditional healing, and consider these when framing discussions about treatment.9 Supporting cultural safety with SPIKES When introducing sensitive treatments like medical cannabis, healthcare professionals can enhance cultural safety by using structured communication tools. One such tool, the SPIKES framework, was originally developed to aid communication of ‘bad news’ in healthcare12, and can be applied to fostering effective communication with diverse patients. Adapted from Buckman 2005 Summary Medical cannabis may offer symptom relief for some patients when clinically appropriate, but how it is introduced matters. Culturally safe practice, guided by structured, empathetic communication models such as SPIKES12, ensures that care is not only clinically sound but also respectful, empowering and patient-centred.3 Cultural safety isn’t a checkbox; it is an ongoing commitment to reflection, understanding, and partnership. Every conversation is an opportunity to make healthcare a safer, more inclusive space for all. Job code: MONT-SGD-2025-0005 | Date of preparation: July 2025

Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder¹ , affecting 12-21% of women of reproductive age.² Despite its widespread occurrence, only 30% of those with PCOS are diagnosed², often only when complications begin to severely impact their quality of life.³ This module explores the potential of medical cannabis as an adjunct treatment for PCOS, offering new hope for managing symptoms and improving patient outcomes. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PCOS Identify conventional interventions for PCOS and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PCOS (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PCOS References ¹ Amiri, Fatemeh Nasiri, et al. “The Experience of Women Affected by Polycystic Ovary Syndrome: A Qualitative Study from Iran.” International Journal of Endocrinology and Metabolism, vol. 12, no. 2, Apr. 2014, https://doi.org/10.5812/ijem.13612. Accessed 26 June 2024. ² Boyle, Jacqueline, and Helena J. Teede. “Polycystic Ovary Syndrome.” Australian Family Physician, vol. 41, no. 10, Oct. 2012, www.racgp.org.au/afp/2012/october/polycystic-ovary-syndrome. Accessed 26 June 2024. ³ Singh, Samradhi, et al. “Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.” Journal of Clinical Medicine, vol. 12, no. 4, Feb. 2023, p. 1454, https://doi.org/10.3390/jcm12041454. Accessed 26 June 2024.

Emotional fluctuations after childbirth are common and typically subside within two weeks.¹ However, when these symptoms persist and interfere with a person's ability to care for themselves or their infant, it may indicate postpartum depression (PPD).¹ Affecting an estimated 6-12% of Australian women², PPD is widespread, yet many hesitate to seek treatment due to concerns around privacy³, fear of judgement, and a lack of adequate support⁴. Even when treatment is sought, conventional options often fall short in fully addressing the symptoms. This module explores the potential role of medical cannabis in helping individuals with PPD, offering an alternative path toward symptom relief. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PPD Identify conventional interventions for PPD and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PPD (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PPD References ¹ Mughal, Saba, et al. “Postpartum Depression.” PubMed, StatPearls Publishing, Jan. 2023, www.ncbi.nlm.nih.gov/books/NBK519070. Accessed 17 June 2024. ² Ogbo, Felix Akpojene, et al. “Determinants of Antenatal Depression and Postnatal Depression in Australia.” BMC Psychiatry, vol. 18, no. 1, Feb. 2018, https://doi.org/10.1186/s12888-018-1598-x. Accessed 17 June 2024. ³ Brummelte, Susanne, and Liisa A. M. Galea. “Postpartum Depression: Etiology, Treatment and Consequences for Maternal Care.” Hormones and Behavior, vol. 77, Jan. 2016, pp. 153–66, https://doi.org/10.1016/j.yhbeh.2015.08.008. Accessed 17 June 2024. ⁴ Zauderer, Cheryl. “Postpartum Depression: How Childbirth Educators Can Help Break the Silence.” Journal of Perinatal Education, vol. 18, no. 2, Jan. 2009, pp. 23–31, https://doi.org/10.1624/105812409x426305. Accessed 17 June 2024.

Premenstrual dysphoric disorder (PMDD) is a complex and disabling condition¹ marked by cognitive, emotional, and physical symptoms in the lead-up to menstruation². Affecting an estimated 3-8% of menstruating individuals³, with 5-8% experiencing severe distress or significant impairment in daily activities⁴, PMDD remains a challenging condition to manage. Without a clear cause, current treatments focus on symptomatic control—targeting mood regulation or hormonal balance—though many patients find limited relief. This module explores the potential of medical cannabis as a therapeutic option for resistant PMDD symptoms, offering a non-hormonal alternative to traditional treatments that may carry reproductive side effects. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PMDD Identify conventional interventions for PMDD and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PMDD (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PMDD References ¹ Osborn, Elizabeth, et al. “Women’s Experiences of Receiving a Diagnosis of Premenstrual Dysphoric Disorder: A Qualitative Investigation.” BMC Women’s Health, vol. 20, no. 1, Oct. 2020, https://doi.org/10.1186/s12905-020-01100-8. Accessed 26 June 2024. ² Hantsoo, Liisa, and C. Neill Epperson. “Premenstrual Dysphoric Disorder: Epidemiology and Treatment.” Current Psychiatry Reports, vol. 17, 2015, https://doi.org/10.1007/s11920-015-0628-3. Accessed 26 June 2024. ³ Halbreich, Uriel, et al. “The Prevalence, Impairment, Impact, and Burden of Premenstrual Dysphoric Disorder (PMS/PMDD).” Psychoneuroendocrinology, vol. 28, no. 3, Aug. 2003, pp. 1–23, https://doi.org/10.1016/s0306-4530(03)00098-2. Accessed 26 June 2024. ⁴ Slavin, Melissa, et al. “Cannabis and Symptoms of PMS and PMDD.” Addiction Research & Theory, vol. 25, no. 5, Mar. 2017, pp. 383–89, https://doi.org/10.1080/16066359.2017.1294165. Accessed 26 June 2024.

While medical cannabis is an effective treatment option for many patients, it’s considered an unapproved good on the TGA’s schedule of drugs. This course is designed to equip healthcare professionals with the skills, knowledge and confidence to navigate the TGA’s Special Access Scheme (SAS) and apply to prescribe medical cannabis to suitable individual patients on a case by case basis using the SAS-B pathway.  We’ll also delve into the broader legal and ethical considerations of prescribing medical cannabis as a treatment option, including risk-mitigation strategies so you can start prescribing medical cannabis to your eligible patients as soon as possible. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Define unapproved good Describe different pathways for accessing and prescribing unapproved goods Explain the differences and correct use of the SAS and Authorised prescriber pathways Apply to prescribe medical cannabis for individual patients using the SAS-B pathway Explain the legal and ethical considerations, and risk-mitigation strategies when prescribing medical cannabis via the SAS-B pathway

While medical cannabis is an effective treatment option for many patients, it’s considered an unapproved good on the TGA’s schedule of drugs. This course is designed to equip healthcare professionals with the skills, knowledge and confidence to navigate the TGA’s Special Access Scheme (SAS) and apply to prescribe medical cannabis to suitable individual patients on a case by case basis using the SAS-B pathway.  We’ll also delve into the broader legal and ethical considerations of prescribing medical cannabis as a treatment option, including risk-mitigation strategies so you can start prescribing medical cannabis to your eligible patients as soon as possible. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Define unapproved good Describe different pathways for accessing and prescribing unapproved goods Explain the differences and correct use of the SAS and Authorised prescriber pathways Apply to prescribe medical cannabis for individual patients using the SAS-B pathway Explain the legal and ethical considerations, and risk-mitigation strategies when prescribing medical cannabis via the SAS-B pathway

Renal conditions can be challenging to manage due to the complexity of symptoms, limitations in treatment options and comorbidities.¹ Preliminary and emerging research has demonstrated medical cannabis' therapeutic potential for treating some symptoms of renal conditions, particularly neuropathic pain and uremia-induced pruritis.² Though it is theorised that medical cannabis treatment may present risks to those with renal conditions – particularly concerning drug-drug-interactions.³ As medical cannabis use continues to grow, healthcare professionals should stay informed about medical cannabis treatment applications in renal conditions, and equipped to provide the best evidence-based guidance.⁴ Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Describe the physiology and key functions of the kidneys Describe the pathophysiology of chronic kidney disease (CKD), acute kidney injury (AKI), autosomal dominant polycystic kidney disease (ADPKD) and renal cancer and recommended conventional treatment options Describe medical cannabis' therapeutic potential for treating symptoms of renal conditions Identify risks, risk management strategies and general considerations of medical cannabis treatment for individuals with renal conditions References Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The Lancet. 2017;389(10075):1238-1252. doi:https://doi.org/10.1016/s0140-6736(16)32064-5 Ho C, Martinusen D, Lo C. A Review of Cannabis in Chronic Kidney Disease Symptom Management. Canadian Journal of Kidney Health and Disease. 2019;6:205435811982839. doi:https://doi.org/10.1177/2054358119828391 Lappin J. Drug Interactions with Cannabis. Society of Cannabis Clinicians. Published July 10, 2024. Accessed February 27, 2025. https://www.cannabisclinicians.org/2024/07/10/drug-interactions-with-cannabis/ Rein JL. The Nephrologistʼs Guide to Cannabis and Cannabinoids. Current Opinion in Nephrology and Hypertension. 2020;29(2):248-257. doi:https://doi.org/10.1097/mnh.0000000000000590

In the current landscape, medical cannabis products are tightly regulated with stringent dispensing requirements. Medical cannabis dispensers (MCDs), and the businesses they represent, are responsible for adhering to all relevant legislation and policy while also implementing best practice dispensing for robust patient-centred care. This fundamental module equips pharmacists with the knowledge and skills to effectively fulfil their essential role in dispensing medical cannabis.  Beyond the technical aspects, pharmacists serve as key advocates for patient care, ensuring the safety, privacy, and well-being of patients throughout their medical cannabis journey. In this module, learners will explore methods to build trust with patients, provide comprehensive education on cannabis products, and ensure compliance with record-keeping and reporting standards. This module also emphasises the critical role of collaboration with healthcare teams to ensure safer, more effective treatment outcomes. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Identify the legal and ethical responsibilities of medical cannabis dispensers (MCDs) Implement respectful communication practices to educate and build safety, trust and rapport with patients Counsel patients on safe use of medical cannabis products – including dosage, titration, administration, storage and identifying and responding to side effects Explain how to store, monitor and maintain medical cannabis products securely Discuss pharmacists' record-keeping obligations when dispensing medical cannabis Collaborate with other health practitioners for a multidisciplinary approach to medical cannabis treatment

The lack of formal education on medicinal cannabis makes it difficult for patients and medical practitioners to discuss medical cannabis as part of a treatment plan, despite a growing demand from patients for alternative medications.1  A report found that general practitioners (GPs) felt uncomfortable discussing medicinal cannabis with patients due to their limited knowledge, concerns about safety, and confusion around the appropriateness of medical cannabis for certain patients.2 This course aims to address this knowledge gap by providing doctors with information on absolute and relative contraindications, adverse events associated with medicinal cannabis, and the social impact around medicinal cannabis on driving and safety-sensitive tasks. Estimated Duration: 1.5 hours Access Duration: 12 months from date of purchase

Medical cannabis use has expanded significantly in recent years,1 offering potential relief for many common conditions and symptoms such as chronic pain, nausea and vomiting, muscle spasms, sleep problems, epilepsy and some mental health conditions.2 While medical cannabis is generally considered to be "well tolerated," health practitioners and professionals must still maintain up-to-date knowledge on key considerations, including:3,4 Legislative contraindications and safety advice Potential adverse effects Drug-to-drug interactions Social and lifestyle impacts This module explores the safety profile and clinical contraindications of medical cannabis within the Australian healthcare setting. Designed for healthcare professionals, it covers key regulatory frameworks, TGA prescribing guidance, and access pathways. Learn to recognise when medical cannabis may be unsuitable, identify potential drug interactions, understand adverse effects, and address concerns such as cognitive impairment, dependence, and driving safety. By the end of this module, you'll be able to apply regulatory knowledge, assess patient suitability, and explain the physiological and behavioural effects associated with medical cannabis use. Preview this module by watching the video above. Estimated Duration: 1 hours Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Identify the primary regulatory bodies overseeing medical cannabis in Australia and explain their roles Explain the origins and scope of the TGA's prescribing guidance documents Describe the current status of medical cannabis products in Australia and identify the TGA's access pathways for unapproved goods Identify conditions for which medical cannabis is contraindicated and associated risks Recount TGA-recommended information to include in a clinical assessment Discuss potential drug-drug interactions in medical cannabis treatment and their underlying mechanisms Explain the safety profile of medical cannabis and potential side effects Describe how THC may affect driving safety and summarise the resulting legislation and guidelines Compare THC’s potential impact on driving with that of other substances Describe cannabis' addictive potential and highlight relevant research gaps in this area Detail the symptoms, mechanisms of action, and potential impacts of cannabis dependence and cannabis use disorder Describe the symptoms of cannabis withdrawal and consider possible treatment options Explain the potential cognitive effects of cannabis use References Australian Health Practitioner Regulation Agency. (2024, February 10). Australian Health Practitioner Regulation Agency - Regulators come together as one million Australians turn to medicinal cannabis treatments. Retrieved from www.ahpra.gov.au website: https://www.ahpra.gov.au/News/2024-02-20-medical-cannabis-treatment.aspx(Therapeutic Goods Administration, 2024) Therapeutic Goods Administration. (2024a, March 1). Medicinal cannabis: access pathways and usage data. Retrieved December 5, 2024, from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-usage-data#patient-access-via-the-special-access-scheme-sas-and-authorised-prescriber-ap-pathway Arnold, J. C. (2021). A primer on medicinal cannabis safety and potential adverse effects. Retrieved from Australian Journal of General Practice website: https://www1.racgp.org.au/ajgp/2021/june/a-primer-on-medicinal-cannabis-safety-and-potentiaTherapeutic Goods Administration, 2024b) Therapeutic Goods Administration. (2024b, November 28). Guidance for the use of medicinal cannabis in Australia: Overview. Retrieved from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/resources/resource/reference-material/guidance-use-medicinal-cannabis-australia-overview